18F-Fluoride PET-CT for Detecting Bone Metastases in RCC

• Research type

  Research Study

• Full title

  A Pilot Study Investigating the Sensitivity of 18F-labelled Sodium Fluoride PET-CT for Detecting Skeletal Metastases in Renal Cell Carcinoma compared to Planar Bone Scintigraphy and Multidetector CT

• IRAS ID

  50542

• Contact name

  Ferdia Gallagher

• Sponsor organisation

  Cambridge University Hospitals NHS Foundation Trust and University of Cambridge

• Eudract number

  2010-024624-20

• ISRCTN Number

  pending

• Research summary

  This study will assess a new test to image bone metastases in patients with renal cancer. Although there are a number of investigations that can identify bone metastases, there is no test that can reliably identify all metastases in all patients. Knowing whether a patient has a bone metastasis can have important implications on the way the patient is treated e.g. it can determine if they have surgery or not. Consequently, we are exploring a new way to detect bone metastases in this disease callefluride PET-CT. It will be compared to two conventional methods for looking at bone metastases: bone scintigraphy (sometimes called a "bone scan") and computed tomography (or "CT")fluride PET-CT has been previously shown to be sensitive for detecting bone metastases in other cancers and this pilot trial will explore its potential role in renal cancer. 10-20 patients will each have a bone scintigram, fluride PET study and a CT. The number and distribution of bone metastases identified on the three studies will be compared to determine ifluride PET-CT is more sensitive at detecting these.

• REC name

  London - Brighton & Sussex Research Ethics Committee

• REC reference

  11/LO/0399

• Date of REC Opinion

  12 Jul 2011

• REC opinion

  Further Information Favourable Opinion